Leadership & Pay ·
Cardiff Oncology appoints Leila Alland as interim CMO and increases authorized shares to 300M
CRDFCardiff Oncology, Inc.
Dr. Roger Sidhu separated from Cardiff Oncology, Inc., and Dr. Leila Alland was appointed interim Chief Medical Officer effective October 23, 2026, under a consulting agreement paying $35,000 monthly until April 22, 2027. The company also filed a Certificate of Amendment to increase its authorized common stock to 300,000,000 shares. Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via PLK1 inhibition.